| 000 | 01931 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516003718.0 | ||
| 264 | 0 | _c20110215 | |
| 008 | 201102s 0 0 eng d | ||
| 022 | _a1969-6213 | ||
| 024 | 7 |
_a10.4244/EIJ30V6I4A75 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aApplegate, Robert J | |
| 245 | 0 | 0 |
_aComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. _h[electronic resource] |
| 260 |
_bEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology _cSep 2010 |
||
| 300 |
_a437-46 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngioplasty, Balloon, Coronary _xinstrumentation |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xtherapy |
| 650 | 0 | 4 |
_aDrug-Eluting Stents _xadverse effects |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 700 | 1 | _aHermiller, James J | |
| 700 | 1 | _aSanz, Mark | |
| 700 | 1 | _aDoostzadeh, Julie | |
| 700 | 1 | _aPierson, Wesley | |
| 700 | 1 | _aSu, Xiaolu | |
| 700 | 1 | _aLansky, Alexandra J | |
| 700 | 1 | _aSudhir, Krishnankutty | |
| 700 | 1 | _aStone, Gregg W | |
| 773 | 0 |
_tEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology _gvol. 6 _gno. 4 _gp. 437-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4244/EIJ30V6I4A75 _zAvailable from publisher's website |
| 999 |
_c20212636 _d20212636 |
||